Better Clinical Trial Safety Data Would Aid Benefit/Risk Analysis – DIA Europe Panel
More work needs to be done on benefit/risk assessments before Phase II/III, industry reps say.
More work needs to be done on benefit/risk assessments before Phase II/III, industry reps say.